Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126749 | 0.90 | TRPA1 (0.42) | TRPA1CNR2MAPTKMT2AMEN1 | |
| SCHEMBL7115999 | 0.89 | TRPA1 (0.42) | TRPA1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7120798 | 0.85 | MAPT (0.49) | MAPTSMN1; SMN2TP53KDM4EALDH1A1 | |
| SCHEMBL7123023 | 0.84 | L3MBTL1 (0.42) | TRPA1KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7061008 | 0.82 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7117071 | 0.81 | CNR2 (0.45) | TRPA1CNR2MAPTKMT2AMEN1 | |
| SCHEMBL6664325 | 0.76 | TRPA1 (0.46) | TRPA1CNR2MAPTKMT2AMEN1 | |
| SCHEMBL6692406 | 0.75 | ALDH1A1 (0.36) | L3MBTL1ALDH1A1 | |
| SCHEMBL7062180 | 0.73 | MTHFD2 (0.39) | MAPTKMT2ASMN1; SMN2TP53LMNA | |
| SCHEMBL7114939 | 0.73 | PRKAA2 (0.39) | TRPA1CNR2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | TRPA1 4726/4885CNR2 4567/4885MAPT 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.